Targeting NFE2L2/KEAP1Mutations in Advanced NSCLC With the TORC1/2 Inhibitor TAK-228

Autor: Paik, Paul K., Fan, Pang-Dian, Qeriqi, Besnik, Namakydoust, Azadeh, Daly, Bobby, Ahn, Linda, Kim, Rachel, Plodkowski, Andrew, Ni, Ai, Chang, Jason, Fanaroff, Rachel, Ladanyi, Marc, de Stanchina, Elisa, Rudin, Charles M.
Zdroj: Journal of Thoracic Oncology; April 2023, Vol. 18 Issue: 4 p516-526, 11p
Abstrakt: Increased insight into the mutational landscape of squamous cell lung cancers (LUSCs) in the past decade has not translated into effective targeted therapies for patients with this disease. NRF2, encoded by NFE2L2, and its upstream regulator, KEAP1, control key aspects of redox balance and are frequently mutated in NSCLCs.
Databáze: Supplemental Index